Ep. 397 - What the U.S. midterms mean for biopharma
From BioCentury This Week · · 28 min
This plays from the publisher's own server. We do not host a copy.
Description
Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner (https://www.biocentury.com/article/661541) and could open a narrow path to bipartisan drug pricing legislation (https://www.biocentury.com/article/661503). On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation. The analysts also unpack full Phase III data (https://www.biocentury.com/article/661524) showing pelacarsen failed across all subgroups and what it means for Lp(a) as a cardio target, highlight SITC abstracts (https://www.biocentury.com/article/661478) on localizing immunotherapy within solid tumors, and discuss argenx’s $550 million upfront buyout (https://www.biocentury.com/article/661512) of Unnatural Products. This episode of the BioCentury This Week podcast has been brought to you by Tigermed (https://www.tigermedgrp.com/).
View full story: https://www.biocentury.com/article/661519
#BiotechPolicy #FDA #DrugPricing #Cardiovascular #Immunotherapy
0:01 Sponsor Message: Tigermed 5:06 FDA Leadership After Midterms 12:41 HHS and Drug Pricing 17:34 Pelacarsen Readout at AHA 22:31 SITC Abstract Highlights 25:57 argenx’s Peptide Deal
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)